Study of AMD473, a New Platinum Drug
Author Information
Author(s): Beale P, Judson I, O'Donnell A, Trigo J, Rees C, Raynaud F, Turner A, Simmons L, Etterley L
Primary Institution: Royal Marsden Hospital
Hypothesis
AMD473 is designed to overcome platinum resistance in cancer treatment.
Conclusion
AMD473 shows promise in treating patients with platinum-resistant tumors and has a manageable toxicity profile.
Supporting Evidence
- AMD473 was able to overcome resistance in cell lines with high levels of glutathione.
- The maximum tolerated dose in preclinical studies was determined to be 45 mg/kg.
- Antitumour activity was noted in several tumour models including human ovarian carcinoma xenografts.
- Patients with a good performance status tolerated higher doses with minimal added toxicity.
- Thrombocytopenia was the most commonly observed toxicity in the study.
Takeaway
AMD473 is a new medicine that helps treat cancer, especially when other treatments don't work anymore.
Methodology
This was an open-label, dose-escalating, single-centre Phase I trial to determine the maximum tolerated dose and pharmacokinetics of AMD473.
Potential Biases
Potential bias due to the single-centre design and the open-label nature of the trial.
Limitations
The study was limited by the heavily pretreated patient population and the small sample size.
Participant Demographics
{"gender":{"male":16,"female":26},"age":{"median":53,"range":"33-71"},"tumour_types":{"ovary":10,"nonsmall_cell_lung":9,"mesothelioma":7,"head_and_neck":6,"colon":3,"other":7}}
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website